Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.

Diabetes · 2009 · PMC2780880 · PMID 19720797

Europe PMC DOI

hedged sentences

0.0610

closest p · 1.2× alpha

0.1107

boldest claim

The sentences

marginally significantP = 0.061so close (0.05 < p ≤ 0.1)

The difference was marginally significant after adjusting for sex, smoking status, and baseline A1C (HR 0.33 [0.10–1.05]; P = 0.061) but failed to achieve the statistical significance after adjusting also for baseline albuminuria (HR 0.56 [0.17–1.82]; P = 0.333).

also in 26,082 other papers

showed a trendP = 0.065so close (0.05 < p ≤ 0.1)

Ala carriers compared with Pro/Pro homozygotes showed a trend with lower incidence of microalbuminuria even after adjusting for sex, smoking status, and baseline A1C (HR 0.48 [95% CI 0.22–1.05]; P = 0.065), but not after adjusting also for baseline albuminuria (HR 0.64 [0.29–1.40]; P = 0.263).

also in 53,322 other papers

a nonsignificant trendP = 0.1107not close (p > 0.1)

RESULTS Baseline characteristics of Ala (Ala/Ala or Ala/Pro) carriers and Pro/Pro homozygotes were similar, with a nonsignificant trend to lower albuminuria ( P = 0.1107) in the 177 Ala carriers.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.